| 11564927 |
Therapeutic compositions, combinations, and methods of use |
Jennifer E. Ring, David T. Weaver, Yan Wang |
2023-01-31 |
$2,967,000 |
| 10532056 |
Therapeutic compositions, combinations, and methods of use |
Jennifer E. Ring, David T. Weaver, Yan Wang |
2020-01-14 |
$3,354,000 |
| 10406158 |
Methods and compositions for treating abnormal cell growth |
Winnie Tam, Qunli Xu |
2019-09-10 |
$1,846,000 |
| 9962385 |
Methods and compositions for treating abnormal cell growth |
Winnie Tam, Qunli Xu |
2018-05-08 |
$4,833,000 |
| 8173779 |
Neutralizing human anti-IGFR antibody |
Yan Wang, Robert Greenberg, Leonard G. Presta, Judith Hailey, Peter Brams +3 more |
2012-05-08 |
|
| 8017735 |
Anti-IGFR1 antibody therapeutic combinations |
Yan Wang, Walter Robert Bishop |
2011-09-13 |
|
| 7998688 |
Inhibition of EMT induction in tumor cells by anti-cancer agents |
Salam A. Shaaban |
2011-08-16 |
|
| 7851181 |
Neutralizing human anti-IGFR antibody |
Yan Wang, Robert Greenberg, Leonard G. Presta, Judith Hailey, Peter Brams +3 more |
2010-12-14 |
|
| 7847068 |
Neutralizing human anti-IGFR antibody |
Yan Wang, Robert Greenberg, Leonard G. Presta, Judith Hailey, Peter Brams +3 more |
2010-12-07 |
|
| 7811562 |
Biomarkers for pre-selection of patients for anti-IGF1R therapy |
Yan Wang, Yaolin Wang, Ming-Cheng Liu |
2010-10-12 |
|
| 7790474 |
p53 modulators |
Bimalendu Dasmahapatra, Bernard R. Neustadt, Mark Demma, Alan K. Mallams, Henry A. Vaccaro |
2010-09-07 |
|
| 7667021 |
Neutralizing human anti-IGFR antibody |
Yan Wang, Robert Greenberg, Leonard G. Presta, Judith Hailey, Peter Brams +3 more |
2010-02-23 |
|
| 7485645 |
17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Timothy J. Guzi, Yi Liu, Ronald J. Doll, Anil K. Saksena, Viyyoor M. Girijavallabhan |
2009-02-03 |
$93,211,000 |
| 7432268 |
17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Timothy J. Guzi, Kamil Paruch, Alan K. Mallams, Jocelyn Rivera, Ronald J. Doll +3 more |
2008-10-07 |
$77,394,000 |
| 7271175 |
17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Timothy J. Guzi, Yi Liu, Ronald J. Doll, Anil K. Saksena, Viyyoor M. Girijavallabhan |
2007-09-18 |
$58,900,000 |
| 7217796 |
Neutralizing human anti-IGFR antibody |
Yan Wang, Robert Greenberg, Leonard G. Presta, Judith Hailey, Peter Brams +3 more |
2007-05-15 |
$76,920,000 |
| 7138396 |
17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Timothy J. Guzi, Kamil Paruch, Alan K. Mallams, Jocelyn Rivera, Ronald J. Doll +3 more |
2006-11-21 |
$65,844,000 |
| 7053091 |
17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Timothy J. Guzi, Yi Liu, Ronald J. Doll, Anil K. Saksena, Viyyoor M. Girijavallabhan |
2006-05-30 |
$33,879,000 |
| 6903102 |
17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Timothy J. Guzi, Kamil Paruch, Alan K. Mallams, Jocelyn Rivera, Ronald J. Doll +3 more |
2005-06-07 |
$55,356,000 |
| 6710037 |
Method of treating androgen-dependent disorders |
Lynn Wang, Richard Bond |
2004-03-23 |
$71,103,000 |
| 6569872 |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
Michael Leach, Mark R. Berardi, Elmer Mirro, Dineshwar Sinha, Mark E. Cartwright +1 more |
2003-05-27 |
$122,037,000 |
| 5461057 |
Hydro-ethano-indeno-pyridines |
Joel G. Berger, David J. Blythin, Ronald J. Doll |
1995-10-24 |
$18,953,000 |